Ambri to evaluate SensiDX in hospitals

Ambri (ASX:ABI) has installed its SensiDX System at the Royal North Shore Hospital in Sydney for evaluation and expects to install a second system at Sydney's St Vincent's Hospital shortly.

The two hospitals will assess the performance of the biosensor-based diagnostic system, in a commercially viable format. The company has spent the last six months ramping up its production capabilities for the technology. Its first diagnostic system is for human chorionic gonadotropin, which indicates preganancy.

"We've demonstrated in a research format that we can make the biosensor work... now we need to test the commercial format," said CEO Dr Jonathan Wright.

The aim of the trial, Wright said, was to independently assess key performance indicators of the technology, namely its sensitivity and reproducibility. He estimated that in the six to eight weeks of the trial, several hundred cartridges would be used, providing good statistical data on the performance of the system. The ability of the system to interface with the hospital's IT systems will also be evaluated.

The company expects to release a report on the progress to commercially viable technology by July or August this year.